<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-32786" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Symmetrical Drug-Related Intertriginous and Flexural Exanthema</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Harbaoui</surname>
            <given-names>Sarra</given-names>
          </name>
          <aff>Charles Nicoles Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Litaiem</surname>
            <given-names>Noureddine</given-names>
          </name>
          <aff>University of Tunis El Manar</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sarra Harbaoui declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Noureddine Litaiem declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>10</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-32786.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), previously known as baboon syndrome, is a symmetrical erythematous rash on the gluteal and intertriginous areas observed after exposure to systemic drugs. This activity reviews the pathogenesis of this condition, the diagnostic criteria, and the most common drugs involved. This activity highlights the role of the interprofessional team in managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;the diagnostic criteria for symmetrical drug-related intertriginous and flexural exanthema.</p></list-item><list-item><p>Identify&#x000a0;the drugs most commonly involved in the symmetrical drug-related intertriginous and flexural exanthema.</p></list-item><list-item><p>Compare the different differential diagnoses of symmetrical drug-related intertriginous and flexural exanthema.</p></list-item><list-item><p>Communicate&#x000a0;interprofessional team strategies to improve care coordination and communication to advance the diagnosis and management of symmetrical drug-related intertriginous and flexural exanthema.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=32786&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=32786">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-32786.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) is a symmetrical erythematous rash on the gluteal and intertriginous areas observed after exposure to systemic drugs.<xref ref-type="bibr" rid="article-32786.r1">[1]</xref>&#x000a0;Previously, in 1984, it was referred to as baboon syndrome due to the distribution of the lesions, which localized to the buttocks and inner thighs (resembling the red rump of baboons) and observed as a response to systemic or local administration of contact allergens and drugs.<xref ref-type="bibr" rid="article-32786.r2">[2]</xref>&#x000a0;Hausermann proposed the term SDRIFE in 2004 as more appropriate for those reactions occurring after exposure to systemic drugs, regardless of prior sensitization.<xref ref-type="bibr" rid="article-32786.r3">[3]</xref>&#x000a0;SDRIFE is distinct from other cutaneous drug reactions due to its typical morphology, distribution, and the absence of systemic findings.</p>
      </sec>
      <sec id="article-32786.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Beta-lactam antibiotics, especially amoxicillin, are among the medications causing symmetrical drug-related intertriginous and flexural exanthema. These agents are the most common triggers.<xref ref-type="bibr" rid="article-32786.r4">[4]</xref>&#x000a0;However, there are reports of many other cases that included non-beta-lactam antibiotics such as pristinamycin, clindamycin, erythromycin, roxithromycin, and cotrimoxazole.<xref ref-type="bibr" rid="article-32786.r3">[3]</xref><xref ref-type="bibr" rid="article-32786.r4">[4]</xref><xref ref-type="bibr" rid="article-32786.r5">[5]</xref> Other anti-infective agents such as nystatin, terbinafine, nystatin, fluconazole, metronidazole, and valacyclovir have also been incriminated.<xref ref-type="bibr" rid="article-32786.r5">[5]</xref><xref ref-type="bibr" rid="article-32786.r6">[6]</xref><xref ref-type="bibr" rid="article-32786.r7">[7]</xref></p>
        <p>Finally, other reports exist of drugs as triggers of SDRIFE, including codeine, pseudoephedrine, cimetidine, allopurinol, heparin, hydroxyurea, oxycodone, naproxen, risperidone, ethyl loflazepate, antihypertensives, iodine radio-contrast media, chemotherapeutic agents and monoclonal antibodies such as infliximab.<xref ref-type="bibr" rid="article-32786.r4">[4]</xref><xref ref-type="bibr" rid="article-32786.r5">[5]</xref><xref ref-type="bibr" rid="article-32786.r7">[7]</xref><xref ref-type="bibr" rid="article-32786.r8">[8]</xref>&#x000a0;Reports also implicate topical agents, including bufexamac and 5-fluorouracil.<xref ref-type="bibr" rid="article-32786.r5">[5]</xref></p>
      </sec>
      <sec id="article-32786.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Symmetrical drug-related intertriginous and flexural exanthema are not very common, and the literature documents a limited number of SDRIFE cases. However, since 1984, over 100 cases of drug-related baboon syndrome or SDRIFE have been reported.<xref ref-type="bibr" rid="article-32786.r9">[9]</xref>&#x000a0;SDRIFE affects patients of any age. According to reported cases, it can present at age&#x000a0;18 months to 84 years.<xref ref-type="bibr" rid="article-32786.r10">[10]</xref> Both sexes are affected, with a male predominance.<xref ref-type="bibr" rid="article-32786.r4">[4]</xref><xref ref-type="bibr" rid="article-32786.r10">[10]</xref></p>
      </sec>
      <sec id="article-32786.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Real pathogenetic mechanisms of symmetrical drug-related intertriginous and flexural exanthema are still unclear. Still, it has been suspected to develop as a result of a type IV delayed hypersensitivity immune response.<xref ref-type="bibr" rid="article-32786.r11">[11]</xref> This notion was supported by immunohistochemical evidence for CD4+ T cell infiltration and the increased endothelial and keratinocyte expression of CD26P-selectin, which recruits type 1 helper T cells to the sites of inflammation.<xref ref-type="bibr" rid="article-32786.r4">[4]</xref></p>
        <p>According to some authors, SDRIFE likely involves a type IVa reaction involving CD4+ Th1 cells and macrophages and a type IVc reaction with cytotoxic CD4 and CD8 T cells.<xref ref-type="bibr" rid="article-32786.r12">[12]</xref>&#x000a0;Nevertheless, this does not explain the occurrence of SDRIFE after the first exposure to a given drug without prior sensitization.<xref ref-type="bibr" rid="article-32786.r3">[3]</xref></p>
        <p>Pathophysiological mechanisms might also include a recall phenomenon due to the reactivation of tissue toxicity at the intertriginous predilection sites, direct interactions of the drugs with immunoreceptors, and anatomical particularities of the large folds (the abundance of eccrine sweat glands, the occlusion).<xref ref-type="bibr" rid="article-32786.r3">[3]</xref><xref ref-type="bibr" rid="article-32786.r5">[5]</xref></p>
      </sec>
      <sec id="article-32786.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The histological features of SDRIFE are not specific and are very variable. Typically, a superficial perivascular infiltrate of mononuclear cells is observed. It includes, in some cases, neutrophils and eosinophils.<xref ref-type="bibr" rid="article-32786.r4">[4]</xref>&#x000a0;However, other features were also reported, including subcorneal pustules, vacuolar changes, hydropic degeneration with subepidermal bullae, and necrotic keratinocytes.<xref ref-type="bibr" rid="article-32786.r13">[13]</xref></p>
      </sec>
      <sec id="article-32786.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The latency of the onset of this condition varies from a few hours to a few days after the causative drug is removed. The basis of diagnosis is mainly on the highly characteristic and stereotypic appearance of the rash. The involvement of the gluteal and intertriginous areas and the symmetry of lesions are key diagnostic features.<xref ref-type="bibr" rid="article-32786.r9">[9]</xref>&#x000a0;The diagnostic criteria for symmetrical drug-related intertriginous and flexural exanthema are exposure to a systemically administered drug with the exclusion of contact allergens; characteristic well-demarcated erythema involving the gluteal, perianal, inguinal, or perigenital area; involvement of at least one intertriginous area; symmetry of the affected areas; and the absence of systemic symptoms.<xref ref-type="bibr" rid="article-32786.r3">[3]</xref></p>
        <p>In the literature, skin lesions are often reported as maculopapular erythema or plaques. Atypical disease courses with pustules, papules, blisters, and descriptions of purpuric lesions also exist in rare cases.<xref ref-type="bibr" rid="article-32786.r9">[9]</xref><xref ref-type="bibr" rid="article-32786.r10">[10]</xref>&#x000a0;SDRIFE typically does not present with mucosal involvement and involvement of the face and palmoplantar surfaces is very uncommon.<xref ref-type="bibr" rid="article-32786.r9">[9]</xref></p>
      </sec>
      <sec id="article-32786.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The diagnosis relies mostly on clinical presentation, history, and exclusion of other causes for a rash. Laboratory investigations are performed to exclude systemic involvement (such as cytopenia and hepatic or renal involvement) but are otherwise not necessary for the diagnosis of SDRIFE.<xref ref-type="bibr" rid="article-32786.r9">[9]</xref>&#x000a0;Patch tests, lymphocyte transformation tests, and drug provocation tests (DPT) can be useful for diagnosis, but their outcomes are highly variable.</p>
        <p>Skin patch tests are usually the preferred means of testing, applied to the previously affected areas. According to previous reports, a patch test gives only up to 50% of patients a positive reaction.<xref ref-type="bibr" rid="article-32786.r3">[3]</xref><xref ref-type="bibr" rid="article-32786.r4">[4]</xref><xref ref-type="bibr" rid="article-32786.r10">[10]</xref> The explanation for these results may be that the systemic agent is not completely absorbed when applied to the skin during patch testing.<xref ref-type="bibr" rid="article-32786.r14">[14]</xref></p>
        <p>Controlled drug-provocation testing is considered the gold standard clinical test and results positively in most patients with SDRIFE.<xref ref-type="bibr" rid="article-32786.r4">[4]</xref> Positive drug provocation testing (DPT) has been reported for cases of SDRIFE with clindamycin, cimetidine, corticosteroids, turbine, and valacyclovir.<xref ref-type="bibr" rid="article-32786.r9">[9]</xref></p>
      </sec>
      <sec id="article-32786.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Symmetrical drug-related intertriginous and flexural exanthema is a self-limiting disease, and treatment involves the withdrawal of the culprit agent and supportive management.<xref ref-type="bibr" rid="article-32786.r9">[9]</xref><xref ref-type="bibr" rid="article-32786.r15">[15]</xref>&#x000a0;Systemic or topical steroids are usually prescribed to speed up the healing process, and antihistamines can be an option for symptomatic management of itching.<xref ref-type="bibr" rid="article-32786.r15">[15]</xref></p>
      </sec>
      <sec id="article-32786.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis may include several conditions such as seborrheic dermatitis, intertrigo, allergic contact dermatitis, inverse psoriasis, granular parakeratosis, Darier disease, and Hailey-Hailey disease. All these dermatoses must be excluded before a drug eruption is to be diagnosed.<xref ref-type="bibr" rid="article-32786.r4">[4]</xref><xref ref-type="bibr" rid="article-32786.r9">[9]</xref></p>
        <p>SDRIFE can also mimic other specific drug reactions such as acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS), and fixed drug eruption (FDE).<xref ref-type="bibr" rid="article-32786.r4">[4]</xref><xref ref-type="bibr" rid="article-32786.r9">[9]</xref><xref ref-type="bibr" rid="article-32786.r16">[16]</xref>&#x000a0;However, AGEP and DRESS characteristically demonstrate a widespread rash with accompanying systemic symptoms. FDE can be easily differentiated from SDRIFE as it characteristically presents asymmetrical acral, genital, and mucosal patches or plaques, usually round or oval, with residual hyperpigmentation.<xref ref-type="bibr" rid="article-32786.r13">[13]</xref><xref ref-type="bibr" rid="article-32786.r15">[15]</xref><xref ref-type="bibr" rid="article-32786.r16">[16]</xref></p>
      </sec>
      <sec id="article-32786.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of SDRIFE is good upon discontinuation of the offending drug.<xref ref-type="bibr" rid="article-32786.r5">[5]</xref><xref ref-type="bibr" rid="article-32786.r9">[9]</xref></p>
      </sec>
      <sec id="article-32786.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Symmetrical drug-related intertriginous and flexural exanthema is considered a benign rash due to its self-limited course, and complications are exceptional.<xref ref-type="bibr" rid="article-32786.r4">[4]</xref></p>
      </sec>
      <sec id="article-32786.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Symmetrical drug-related intertriginous and flexural exanthema is a drug reaction associated with beta-lactam antibiotics, radiocontrast media, monoclonal antibodies, and many other drugs. Considering the widespread use of these treatments, patients should always be aware of the possibility of a drug reaction and consult their doctor immediately.</p>
      </sec>
      <sec id="article-32786.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>A detailed history and complete physical examination are mandatory in diagnosing cases of SDRIFE. Symmetrical drug-related intertriginous and flexural exanthema is an uncommon drug reaction that can easily be misdiagnosed or undiagnosed unless the relationship between the history of drug intake and the nature of the skin eruption is well established; this may imply that the actual incidence of SDRIFE is higher than previously thought.</p>
        <p>Clinicians, including physicians,&#x000a0;pharmacists, and nurse practitioners, must work together in an interprofessional team approach to identify this rare disorder and then provide treatment, primarily via the withdrawal of the offending agent. The clinician must collaborate with the pharmacist to determine the agent causing the condition.&#x000a0;Clinicians&#x000a0;can counsel the patient, administer supportive care, and answer patient questions while working with the pharmacist to determine the best means to withdraw the offending medication. The pharmacist can also vet the prescribing of symptomatic care (eg, steroids, etc, and&#x000a0;clinicians&#x000a0;can monitor both the withdrawal of the causative agent and the effectiveness of supportive care. This interprofessional approach drives outcomes positively.</p>
      </sec>
      <sec id="article-32786.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=32786&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=32786">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/symmetrical-drug-related-intertriginous-and-flexural-exanthema/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=32786">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/32786/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=32786">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-32786.s16">
        <title>References</title>
        <ref id="article-32786.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohapatra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Panda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kar</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Raj</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Symmetric Drug-related Intertriginous and Flexural Exanthema due to Itraconazole: An Uncommon Side Effect of a Commonly Used Drug.</article-title>
            <source>Indian Dermatol Online J</source>
            <year>2017</year>
            <season>Nov-Dec</season>
            <volume>8</volume>
            <issue>6</issue>
            <fpage>501</fpage>
            <page-range>501-503</page-range>
            <pub-id pub-id-type="pmid">29204404</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32786.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andersen</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Hjorth</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Menn&#x000e9;</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>The baboon syndrome: systemically-induced allergic contact dermatitis.</article-title>
            <source>Contact Dermatitis</source>
            <year>1984</year>
            <month>Feb</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>97</fpage>
            <page-range>97-100</page-range>
            <pub-id pub-id-type="pmid">6232098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32786.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>H&#x000e4;usermann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Harr</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bircher</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome?</article-title>
            <source>Contact Dermatitis</source>
            <year>2004</year>
            <season>Nov-Dec</season>
            <volume>51</volume>
            <issue>5-6</issue>
            <fpage>297</fpage>
            <page-range>297-310</page-range>
            <pub-id pub-id-type="pmid">15606657</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32786.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nespoulous</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Matei</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Charissoux</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>B&#x000e9;dane</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Assikar</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) associated with pristinamycin, secnidazole, and nefopam, with a review of the literature.</article-title>
            <source>Contact Dermatitis</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>79</volume>
            <issue>6</issue>
            <fpage>378</fpage>
            <page-range>378-380</page-range>
            <pub-id pub-id-type="pmid">30062790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32786.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Magnolo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Metze</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>St&#x000e4;nder</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pustulobullous variant of SDRIFE (symmetrical drug-related intertriginous and flexural exanthema).</article-title>
            <source>J Dtsch Dermatol Ges</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>657</fpage>
            <page-range>657-659</page-range>
            <pub-id pub-id-type="pmid">28514083</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32786.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x0015e;ikar Akt&#x000fc;rk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bayramg&#x000fc;rler</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Salman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Y&#x00131;ld&#x00131;z</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Odyakmaz Demirsoy</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by oral metronidazole.</article-title>
            <source>Cutan Ocul Toxicol</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>337</fpage>
            <page-range>337-8</page-range>
            <pub-id pub-id-type="pmid">24938451</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32786.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daito</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hanada</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Katoh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Katoh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sakamoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Asai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Takenaka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kishimoto</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Symmetrical drug-related intertriginous and flexural exanthema caused by valacyclovir.</article-title>
            <source>Dermatology</source>
            <year>2009</year>
            <volume>218</volume>
            <issue>1</issue>
            <fpage>60</fpage>
            <page-range>60-2</page-range>
            <pub-id pub-id-type="pmid">18974630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32786.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnold</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Hausermann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bach</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bircher</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Recurrent flexural exanthema (SDRIFE or baboon syndrome) after administration of two different iodinated radio contrast media.</article-title>
            <source>Dermatology</source>
            <year>2007</year>
            <volume>214</volume>
            <issue>1</issue>
            <fpage>89</fpage>
            <page-range>89-93</page-range>
            <pub-id pub-id-type="pmid">17191055</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32786.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Symmetrical drug-related intertriginous and flexural exanthema.</article-title>
            <source>Curr Opin Allergy Clin Immunol</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>313</fpage>
            <page-range>313-8</page-range>
            <pub-id pub-id-type="pmid">21659857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32786.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karadag</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Ozlu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Akdeniz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Uzuncakmak</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Turkoglu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Ozkanli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zemheri</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Oral mucosal involvement and petechial lesions: a SDRIFE case with unusual findings.</article-title>
            <source>Cutan Ocul Toxicol</source>
            <year>2016</year>
            <volume>35</volume>
            <issue>2</issue>
            <fpage>157</fpage>
            <page-range>157-9</page-range>
            <pub-id pub-id-type="pmid">26339719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32786.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Weintraub</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Mostaghimi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Symmetrical Drug-related Intertriginous and Flexural Exanthema Induced by Doxycycline.</article-title>
            <source>Cureus</source>
            <year>2017</year>
            <month>Nov</month>
            <day>10</day>
            <volume>9</volume>
            <issue>11</issue>
            <fpage>e1836</fpage>
            <pub-id pub-id-type="pmid">29340257</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32786.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huynh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hughey</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>McKay</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Carney</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sami</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Systemic drug-related intertriginous and flexural exanthema from radio contrast media: A series of&#x000a0;3 cases.</article-title>
            <source>JAAD Case Rep</source>
            <year>2015</year>
            <month>May</month>
            <volume>1</volume>
            <issue>3</issue>
            <fpage>147</fpage>
            <page-range>147-9</page-range>
            <pub-id pub-id-type="pmid">27051713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32786.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bulur</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Keseroglu</surname>
                <given-names>HO</given-names>
              </name>
              <name>
                <surname>Saracoglu</surname>
                <given-names>ZN</given-names>
              </name>
              <name>
                <surname>G&#x000f6;n&#x000fc;l</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Symmetrical drug-related intertriginous and flexural exanthema (Baboon syndrome) associated with infliximab.</article-title>
            <source>J Dermatol Case Rep</source>
            <year>2015</year>
            <month>Mar</month>
            <day>31</day>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>12</fpage>
            <page-range>12-4</page-range>
            <pub-id pub-id-type="pmid">25932057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32786.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Labadie</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Florek</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Croitoru</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Krunic</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>First case of symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) due to Berberine, an over-the-counter herbal glycemic control agent.</article-title>
            <source>Int J Dermatol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>57</volume>
            <issue>9</issue>
            <fpage>e68</fpage>
            <page-range>e68-e70</page-range>
            <pub-id pub-id-type="pmid">29808929</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32786.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weiss</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kinaciyan</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by mefenamic acid.</article-title>
            <source>JAAD Case Rep</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>89</fpage>
            <page-range>89-90</page-range>
            <pub-id pub-id-type="pmid">30581942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32786.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Lan</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by golimumab.</article-title>
            <source>Int J Dermatol</source>
            <year>2017</year>
            <month>May</month>
            <volume>56</volume>
            <issue>5</issue>
            <fpage>571</fpage>
            <page-range>571-572</page-range>
            <pub-id pub-id-type="pmid">28217835</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
